Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Endogenous α-Klotho is a common target in atherosclerosis and calcific aortic valve disease

  • Martín Núñez, Ernesto
  • González-Luis, Ainhoa
  • Perdomo-Ramírez, Ana
  • Tagua, Víctor G.
  • Ferri, Carla
  • Rodríguez-Ramos, Sergio
  • Cerro-López, Purificación
  • López-Castillo, Ángel
  • Delgado-Molinos, Alejandro
  • Martín-Olivera, Alberto
  • Fernández Celis, Amaya
  • Garaikoetxea, Mattie
  • Goñi Olóriz, Miriam
  • San Ildefonso-García, Susana
  • Ibarrola, Jaime
  • Jover, Eva
  • Mora-Fernández, Carmen
  • Donate-Correa, Javier
  • López Andrés, Natalia
  • Navarro-González, Juan F.
Although atherosclerotic vascular disease (ASVD) and calcific aortic stenosis (AS) are distinct clinical entities, inflammation is a common driving force. The contribution of endogenous α-Klotho, an anti-aging protein, in the vasculature and aortic valve (AV) as an inflammatory mediator of such diseases remains unclear. We investigated α-Klotho expression using qPCR, ELISA, and immunohistochemistry in vascular (aorta, carotid, and femoral) and AV tissue samples from patients with ASVD (n = 112) and calcific AS (n = 172), respectively. We also determined circulating levels of soluble α-Klotho. We assessed α-Klotho associations with inflammatory and calcification markers. In vitro, we treated human vascular smooth muscle cells (VSMCs) and valve interstitial cells (VICs) with interleukin (IL)-1a and high-phosphate (HP) medium, respectively, and we evaluated the effects a-Klotho silencing and recombinant a-Klotho (rKlotho) supplementation. α-Klotho expression was significantly reduced in atherosclerotic vessels and stenotic AVs. Vascular expression varied across territories, with the lowest levels in the carotids. In stenotic AVs, α-Klotho expression was lower in fibro-calcified areas compared to "healthy" regions. Endogenous tissue α-Klotho and circulating soluble α-Klotho were inversely associated with local and systemic inflammatory markers and, in AVs, with osteogenic-related markers. In vitro, pro-inflammatory stimuli downregulated α-Klotho gene expression in VSMCs and VICs. α-Klotho silencing amplified inflammatory responses in both cell types and promoted VIC calcification, whereas rKlotho attenuated inflammation and inhibited osteogenic differentiation. These findings suggest endogenous α-Klotho plays a central role in the inflammation underlying ASVD and calcific AS., This work was supported by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, Fondo Europeo de Desarrollo Regional, "Una manera de hacer Europa" (PI13/01736, PI16/00024, PI19/00035, PI21/01037, PI23/00168, PI24/01020, PI25/00057; RD21/0005/0013 -Plan de Recuperacion, ´ Transformacion ´ y Resiliencia. Union ´ Europea - NextGenerationEU-, RD24/0004/0022-ISCIII and co-funded by the European Union) and Departamento de Salud del Gobierno de Navarra (GNa01/21). E.M.N. is supported by a Sara Borrell fellowship (CD24/00070, ISCIII). A.G.L. is supported by a PFIS PhD studentship (FI22/00213, ISCIII). A.P.R. is supported by a contract from RICORS2040-RENAL (RD24/0004/0025, ISCIII and cofunded by the European Union). J.I. is supported by Ramon y Cajal Fellowship (RYC2023-043288-I). E.J. and J.D.C are supported by contracts from the Miguel Servet Programme (CP24/00091 and CP20/00122 respectively, ISCIII).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Chemerin activation of Toll-like receptor 4 drives mineralocorticoid receptor-mediated aortic valve remodeling in chronic kidney disease

  • Sánchez-Bayuela, Tania
  • Soulié, Matthieu
  • Garaikoetxea, Mattie
  • Fernández Celis, Amaya
  • López Andrés, Natalia
  • Jaisser, Frederic
BACKGROUND: Aortic stenosis is the most common valvular heart disease, and its progression is accelerated in chronic kidney disease (CKD), where multiple circulating abnormalities worsen its pathophysiology. This study examined the impact of CKD-related aldosterone excess, focusing on mineralocorticoid receptor signaling and its crosstalk with the innate immune pathway mediated by Toll-l ike receptor 4 (TLR4) in aortic valve (AV) interstitial cells and AV tissue. METHODS: For the study, we conducted in vivo studies using a CKD rat model challenged with high phosphate, followed by ex vivo analysis of AVs. In parallel, primary rat and human valve interstitial cells were used in vitro to evaluate inflammatory, fibrotic, and osteogenic responses to aldosterone and to identify the key signaling pathways involved. Human AVs from patients with aortic stenosis were also analyzed. Quantitative polymerase chain reaction, western blot, and ELISA were used to characterize these pathways. RESULTS: Mineralocorticoid receptor activation emerged as a central driver of aortic stenosis progression in CKD, promoting valve interstitial cell differentiation, inflammation, fibrosis, and calcification through activation of the TLR4-myeloid differentiation primary response 88 innate immunity pathway in response to aldosterone. Moreover, chemerin was identified as a downstream effector of the mineralocorticoid receptor that activates TLR4, further enhancing remodeling and calcification in AVs and valve interstitial cells. These results were corroborated in human stenotic AV samples from patients with CKD. CONCLUSIONS: Collectively, the study defines a novel mineralocorticoid receptor-TLR4-chemerin axis that mediates aldosterone-driven inflammatory and calcific processes in CKD, in both a rat model and in vitro systems., This work was funded by grants from Inserm, ANR NGAL-HT (ANR-19-CE14-0013), ANR MIRAVALVE (ANR-23-CE14-0016-01), Instituto de Salud Carlos III, the European Regional Development Fund: 'A way of making Europe' (PI24/01020), the IRP Inserm Miravac-CKD grant, and the Fédération Française de Cardiologie grant (601-FFC-JAISSER-Dotation 2025).